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Cell lines established from the lepidopteran insect Spodoptera frugiperda (fall armyworm; Sf9) are used
routinely as hosts for the expression of foreign proteins by recombinant baculovirus vectors. We have examined
the pathway of protein glycosylation and secretion in these cells, using human tissue plasminogen activator
(t-PA) as a model. t-PA expressed in Sf9 cells was both N glycosylated and secreted. At least a subset of the
N-linked oligosaccharides in extracellular t-PA was resistant to endo-o-N-acetyl-D-glucosaminidase H, which
removes immature, high-mannose-type oligosaccharides. This refutes the general conclusion from previous
studies that Sf9 cells cannot process immature N-linked oligosaccharides to an endo-4-N-acetyl-D-glucosamini-
dase H-resistant form. A nonglycosylated t-PA precursor was not detected in Sf9 cells, even with very short
pulse-labeling times. This suggests that the mammalian signal sequence of t-PA is efficiently recognized in Sf9
cells and that it can mediate rapid translocation across the membrane of the rough endoplasmic reticulum,
where cotranslational N glycosylation takes place. However, t-PA was secreted rather slowly, with a half-time
of about 1.6 h. Thus, a rate-limiting step(s) in secretion occurs subsequent to translocation and N glycosylation
of the t-PA polypeptide. Treatment of Sf9 cells with tunicamycin, but not with inhibitors of oligosaccharide
processing, prevented the appearance of t-PA in the extracellular medium. This suggests that N glycosylation
per se, but not processing of the N-linked oligosaccharides, is required directly or indirectly in baculovirus-
infected Sf9 cells for the secretion of t-PA. Finally, the relative efficiency of secretion decreased dramatically
with time of infection, suggesting that the Sf9 host cell secretory pathway is compromised during the later stages
of baculovirus infection.
The use of recombinant baculoviruses as expression vec-
tors has intensified in recent years to the extent that more
than 50 different genes have now been expressed in this
system (reviewed in reference 19). In general, this approach
involves the construction and isolation of recombinant bac-
uloviruses in which the coding sequence for a chosen gene
has been inserted behind the promoter for the nonessential
viral gene, polyhedrin (25, 31, 33). The overwhelming ad-
vantage of baculovirus vectors is that they express many
foreign gene inserts at extraordinarily high levels, as a result
of the relative strength of the polyhedrin promoter. How-
ever, the use of baculovirus vectors relies upon host cells
derived from lepidopteran insects, and historically, this has
contributed a measure of uncertainty to the system. Little is
known about the molecular mechanisms of protein process-
ing in these invertebrate cells, and most of the genes that
have been inserted into the viral expression vector are
derived from vertebrate species. Thus, it has been difficult to
predict whether authentic and/or functional proteins could
be produced with this system.
In several published studies of baculovirus-mediated gene
expression, this problem has been addressed by analyses of
the structures and/or functions of various foreign protein
products synthesized in insect cells. The usual host cell is
Sf9, a clonal isolate of the IPLB-Sf2l-AE line established
from Spodoptera frugiperda (fall armyworm), and the usual
result is that the proteins are essentially authentic and are
antigenically and/or biologically active (reviewed in refer-
ence 19). However, more detailed investigations have sug-
gested that Sf9 cells and mammalian cells exhibit some
differences in their basic mechanisms of protein glycosyl-
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ation (10, 17, 28, 44). Glycoproteins expressed in Sf9 cells
clearly undergo the initial step ofN glycosylation, defined in
mammalian cells as the cotranslational addition of a high-
mannose oligosaccharide to the polypeptide chain (reviewed
in reference 14). However, current data suggest that, unlike
their mammalian counterparts, Sf9 cells are incapable of
processing the immature oligosaccharide to a complex form.
So far, this conclusion has been based upon the finding that
glycoproteins derived from Sf9 cells remain sensitive to
endo-,-N-acetyl-D-glucosaminidase H (endo-H; 38), an endo-
glycosidase capable of removing only high-mannose oligo-
saccharide side chains. Direct chemical analyses of N-linked
oligosaccharides isolated from mammalian glycoproteins
synthesized in Sf9 cells has not yet been reported.
Tissue plasminogen activator (t-PA) functions to convert
the zymogen, plasminogen, to its enzymatically active form,
plasmin, which then acts directly to cause the lysis of blood
clots and the destruction of clotting factors. t-PA has direct
therapeutic use in humans as a thrombolytic agent and
appears to reduce mortality in heart attack victims (34). The
human t-PA polypeptide has a calculated molecular mass of
about 59,000 (59 kilodaltons [kDa]; 24) and contains a
cleavable amino-terminal signal sequence for translocation
across the membrane of the rough endoplasmic reticulum
from amino acid 1 to amino acid 20, a prosequence from
amino acid 20 or 23 to amino acid 35, and four potential N
glycosylation sites (24). Biochemical studies of t-PA purified
from mammals have shown that it may occur in several
forms (26, 27, 29, 42, 43). The intact, or single-chain, t-PA
polypeptide can undergo proteolysis to produce a two-chain
form, consisting of disulfide-linked A (heavy) and B (light)
chains. It has been shown that N glycosylation may occur at
either two or three of the four potential recognition sites. All
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molecules appear to undergo glycosylation at one site in
each of the A and B chains (variant II), while a subpopula-
tion is glycosylated at an additional site in the A chain
(variant I). The N-linked oligosaccharide on the A chain of
mammalian variant II t-PA has a high-mannose structure,
while that on the B chain is of the complex type, as is the
additional oligosaccharide on the A chain of mammalian
variant I t-PA. The reported apparent molecular mass values
for single-chain t-PA range from 63 to 72 kDa, with a
difference of about 3 kDa between variants I and II. Upon
reduction, the two-chain form of t-PA is converted to free B
chains of about 33 kDa and A chains of about 37 kDa (variant
II) or 40 kDa (variant I).
In this study, we have used human t-PA as a model to
probe the pathway of N glycosylation and secretion in
baculovirus-infected Sf9 cells. New information was ob-
tained on several aspects of this pathway. Pulse-chase
experiments indicated that the mammalian signal sequence
of t-PA is recognized efficiently in Sf9 cells and that it can
mediate rapid translocation across the membrane of the
rough endoplasmic reticulum, where N glycosylation of the
polypeptide takes place. A previously unrecognized degree
of N-linked oligosaccharide processing was documented in
Sf9 cells, and a role for cellular glucosidase(s) in the Sf9 cell
N glycosylation pathway was implicated. Finally, the rela-
tionship between N glycosylation and secretion of t-PA was
investigated, as was the effect of virus infection on the
secretion on the human t-PA from Sf9 cells. We speculate
that the results described in this study reflect, in a more
general sense, characteristics of the leptidopteran insect cell
pathway which accomplish the N glycosylation and secre-
tion of foreign or naturally occurring glycoproteins.
MATERIALS AND METHODS
Cells and viruses. The Sf9 clone of IPLB-Sf21-AE cells
(41) was maintained as a monolayer culture in TN-MFH
medium containing 10% heat-inactivated fetal bovine serum
(Hazelton Research Products, Inc., Lenexa, Kans.) and
subcultured every 3 days at 2.0 x 106 to 2.5 x 106 cells per
flask (35). The E2 strain of wild-type Autographa californica
nuclear polyhedrosis virus (AcMNPV; 32) and 373-t-PA, the
recombinant baculovirus encoding human t-PA, were prop-
agated and titrated in Sf9 cells as described previously (35).
The construction and isolation of 373-t-PA were accom-
plished by established methods (35) as described elsewhere
(V. A. Luckow and M. D. Summers, Virology, in press).
Infections and metabolic labeling. Sf9 cells were seeded at
106 cells and allowed to attach to the plastic culture vessel
for at least 1 h at 28°C. The medium was drained, and 1.0 ml
of virus suspension was added to a multiplicity of infection
of about 50 PFU per cell. The cells were incubated for
another hour at 28°C, the inoculum was removed, and the
infected cells were fed with about 5 ml of Grace medium
containing 0.5% heat-inactivated fetal bovine serum and
antibiotics (maintenance medium; D. Broussard and M.
Summers, J. Invert. Pathol., in press). The generic meta-
bolic labeling procedure was to incubate the cells at 28°C
until 20 h postinfection (hpi), remove the medium, and label
the cells for 4 h with methionine-free Grace medium con-
taining 100 ,uCi of Translabel (ICN Biomedicals, Inc., Irvine,
Calif.; a mixture of about 80% [35S]methionine and about
20% [35S]cysteine; specific activity, about 1,200 Ci/mmol)
per ml. For inhibitor experiments, the labeling period was
preceeded by a 4-h pretreatment, and the inhibitors were
included in the labeling medium.
For pulse-chase analyses, we used a method adapted by
C. Oker-Blom and M. Summers (submitted for publication).
Sf9 cells were grown as suspension instead of monolayer
cultures, and an appropriate number of cells were pelleted
gently, suspended in 1.0 ml of virus suspension at a multi-
plicity of infection of about 50 PFU per cell, and incubated
for 1 h at 28°C. The infected cells were pelleted, the
inoculum was removed, and the cells were suspended in
maintenance medium and incubated at 28°C until 23 hpi. At
that time, the infected cells were pelleted, suspended in
methionine-free Grace medium, and incubated for 1 h at
28°C. Following this starvation period, the cells were pulse-
labeled either for 5 min with 500 ,Ci of Translabel per ml or
for 15 min with 200 ,Ci of Translabel per ml in methionine-
free Grace medium. After being labeled, the cells were
immediately diluted 1:10 in chase medium (Grace medium
containing 0.5% heat-inactivated fetal bovine serum, 5x-
concentrated amino acids, and 10 ,ug of cycloheximide per
ml), pelleted, and resuspended in fresh chase medium.
Zero-time samples were taken at this point, the cells were
returned to 28°C, and samples were removed at different
times according to the requirements of the experiment.
Extractions, immunoprecipitation, gel electrophoresis, and
Western blot (immunoblot) analysis. After pulse-label or
pulse-chase, cellular fractions were prepared and t-PA was
analyzed by immunoprecipitation and sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis (SDS-PAGE) or by
SDS-PAGE and Western blotting. The three cellular frac-
tions of interest are defined here as extracellular, intracellu-
lar, and insoluble. The extracellular fraction consisted of the
labeling medium recovered from the cells, clarified for 0.5
min in a microcentrifuge (model 235C; Fisher Scientific Co.,
Pittsburgh, Pa.), and supplemented with Nonidet P-40 (NP-
40) to a final concentration of 1%. The intracellular fraction
was prepared by treating the cells for 20 min on ice with
extraction buffer (50 mM Tris hydrochloride [pH 8.0] con-
taining 100 mM NaCl, 1% NP-40, and 500 Kallikrein inacti-
vating units of aprotinin per ml), microcentrifuging the
extract for 15 min, and harvesting the supernatant fluid. The
insoluble fraction was prepared by boiling the pellet from the
intracellular fraction for 5 min in protein sample buffer (50
mM Tris hydrochloride [pH 6.8] containing 4% SDS and 4%
P-mercaptoethanol), diluting 1:100 in extraction buffer,
microcentrifuging the extract for 15 min, and harvesting the
supernatant fluid.
Immunoprecipitations were performed by incubating ex-
tracts overnight on ice with goat anti-human melanoma t-PA
immunoglobulin G (American Diagnostica, New York,
N.Y.) or rabbit anti-polyhedrin at a final concentration of 2.5
,ug/ml. Immune complexes were harvested by adding 0.1 ml
of a fixed Staphylococcus aureus Cowan 1 suspension pre-
pared by the method of Kessler (13), shaking the mixture for
30 min on ice, and washing the immunoprecipitates three
times with a detergent wash buffer (extraction buffer supple-
mented with 0.1% SDS and 1% sodium deoxycholate). The
washed immunoprecipitates were disrupted by being boiled
for 3 min in protein sample buffer, the samples were clari-
fied, and the supernatants were analyzed by SDS-PAGE
with the discontinuous system of Laemmli (18). Autoradio-
grams were obtained by direct exposure of the dried gels to
XAR-5 film (Eastman Kodak Co., Rochester, N.Y.) at room
temperature.
For Western analysis (40), proteins separated by SDS-
PAGE were electrophoretically transferred to nitrocellulose
sheets with a semidry apparatus in accordance with the
recommendations of the manufacturer (American Bionetics,
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Inc., Hayward, Calif.). After transfer, the sheets were
treated with blocking buffer (25 mM Tris hydrochloride [pH
7.4] containing 0.14 M NaCl, 0.1% NP-40, 1% nonfat dry
milk, and 0.02% NaN3) for at least 1 h at room temperature
and probed for 30 min at room temperature with goat
anti-human t-PA at a dilution of 1:500 in blocking buffer. The
sheets were washed three times with blocking buffer and
treated for another 30 min at room temperature with alkaline
phosphatase-conjugated rabbit anti-goat immunoglobulin G
(Organon Teknika, Malvern, Pa.). After three more washes
with blocking buffer, the sheets were rinsed with 25 mM Tris
hydrochloride [pH 7.4] containing 0.14 M NaCl, blotted, and
developed with a standard alkaline phosphatase color reac-
tion (1).
Endoglycosidase reactions. Endo-H and N-glycanase were
obtained from Genzyme, Inc. (Boston, Mass.). t-PA was
immunoprecipitated from extracellular or intracellular frac-
tions of 373-t-PA-infected Sf9 cells as described above,
except that antigen-antibody complexes were disrupted by
being boiled in 0.5% SDS and 0.1 M P-mercaptoethanol,
prepared in water. The disrupted samples were clarified, and
the supernatant fluid was harvested and diluted threefold
with 50 mM sodium phosphate (pH 5.5). Endo-H was added
to a final concentration of 200 mU/ml or N-glycanase was
added to a final concentration of 40 U/ml, and the mixtures
were incubated for at least 16 h at 37°C. After the treatment
period, the samples were boiled in an equal volume of
2 x -concentrated protein sample buffer and analyzed by
SDS-PAGE.
MOCK 373-TPA AcMNPV
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FIG. 1. Specific immunodetection of human t-PA in 373-t-PA-
infected Sf9 cells. Mock-, 373-t-PA-, or AcMNPV-infected Sf9 cells
were pulse-labeled with 100 ,uCi of [35S]Translabel per ml from 20 to
24 hpi. Extracellular (XC), intracellular (IC), and insoluble (IN)
fractions were prepared, and each was immunoprecipitated with
either polyclonal rabbit anti-polyhedrin serum (odd lanes) or poly-
clonal goat anti-t-PA serum (even lanes). Immune complexes were
adsorbed with fixed S. aureus Cowan 1 cells, washed, disrupted,
and analyzed by SDS-PAGE. The numbers on the right or left
represent molecular masses (in thousands) of standards run on each
gel.
RESULTS
Specific immunodetection of human t-PA expressed in insect
cells. Relative to many other recombinant proteins that have
been expressed with baculovirus vectors, t-PA is expressed
at low levels (Luckow and Summers, in press). Therefore, it
was desirable to establish a radioimmunoprecipitation pro-
cedure for the specific detection of t-PA-related polypep-
tides. The results (Fig. 1) of multiple experiments showed
that polyclonal goat anti-t-PA serum precipitated only one
extracellular polypeptide of about 62 kDa (lane 8) and
predominantly one intracellular polypeptide of about 65 kDa
(lane 10) from 373-t-PA-infected Sf9 cells. The vast majority
of the intracellular t-PA was extractable with NP-40, as only
small additional amounts were extracted from the residual
NP-40-insoluble fraction by boiling in SDS plus mercapto-
ethanol (lane 12). Immunoprecipitation of the 62- and 65-kDa
proteins was specific, as evidenced by their absence in
samples from mock-infected (lanes 1 to 6) or wild-type
baculovirus (AcMNPV)-infected (lanes 13 to 18) cells immu-
noprecipitated with either anti-polyhedrin (odd lanes) or
anti-t-PA (even lanes) and in samples from 373-t-PA-infected
cells immunoprecipitated with anti-polyhedrin (lanes 7, 9,
and 11). Conversely,- minor amounts of several other pro-
teins were nonspecifically precipitated from the intracellular
fraction of 373-t-PA-infected Sf9 cells by anti-t-PA, as evi-
denced by their presence in control samples (e.g., with
anti-polyhedrin in lane 9) and their nonreactivity with anti-
t-PA in Western analyses (data not shown).
These results indicate that the 65-kDa polypeptide is the
major form of t-PA expressed in 373-t-PA-infected Sf9 cells
and that the 62-kDa polypeptide is the major form secreted
from the cells. The masses of both proteins fall within the
range of values reported for the N-glycosylated single-chain
forms of t-PA from mammalian cells. It should be noted that
aprotinin was included in all extraction buffers to inhibit the
proteolytic conversion of the single-chain forms of t-PA to
the smaller two-chain products (42). Nevertheless, we occa-
sionally observed minor amounts of the reduced two-chain
products, seen in Fig. 1 as the specifically precipitated
intracellular protein of about 33 kDa (lane 10).
Glycosylation of human t-PA expressed in insect cells.
Treatments with endo-H or N-glycanase were performed to
determine directly if t-PA underwent N glycosylation in
Sf9 cells. Endo-H removes only high-mannose N-linked
oligosaccharides from glycoproteins, while N-glycanase
[peptide-N4-(N-acetyl-3-glucosaminyl)asparagine amidase;
37] removes both high-mannose and complex N-linked oli-
gosaccharides from glycoproteins. Tunicamycin (TM), a
well-established inhibitor of all N glycosylation (36), was
used to obtain nonglycosylated t-PA from 373-t-PA-infected
cells as a marker. Among several major bands immunopre-
cipitated from TM-treated cells with anti-t-PA (e.g., see Fig.
2A, lane 4), only the one with a mass of about 58 kDa was
specific, as shown by Western analysis (e.g., see Fig. 5). The
other major bands observed in the presence of TM (80, 52,
32, and 31 kDa) might have been viral or cellular polypep-
tides which coprecipitated by virtue of a physical association
with nonglycosylated t-PA; this possibility is under further
investigation.
Treatment of the intracellular form of t-PA (Fig. 2A) with
either endo-H (lane 6) or N-glycanase (lane 5) clearly re-
duced its size relative to the control (lane 7). These results
indicate that intracellular t-PA is N glycosylated in Sf9 cells
and that it contains high-mannose oligosaccharides. Similar
results were obtained by treatment of the extracellular form
of t-PA with these two endoglycosidases. Furthermore, it
was clear that the product of N-glycanase cleavage (lane 3)
was smaller than that of endo-H cleavage (lane 2). This was
probably true for intracellular t-PA as well, but with a
smaller difference in the sizes of the endo-H and N-glyca-
nase reaction products (compare lanes 5 and 6). These
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FIG. 2. Endoglycosidase analysis of insect cell-derived t-PA.
373-t-PA-infected Sf9 cells were labeled with [35S]Translabel, and
t-PA was immunoprecipitated from the extracellular (XC) and
intracellular (IC) fractions as described in the legend to Fig. 1.
Immune complexes were washed, and t-PA was recovered and
treated with buffer alone (C), 200 mU of endo-H (E) per ml, or 40 U
of N-glycanase (N) per ml as described in Materials and Methods.
The reaction products were disrupted and analyzed by SDS-PAGE.
t-PA immunoprecipitated from the intracellular fraction of infected
Sf9 cells treated for 8 h with 1 ,ug of TM (T) per ml (lanes 4, 8, and
12) served as a marker for the nonglycosylated protein. Note that
only the upper band of the intense doublet from TM-treated cells (58
kDa) was antigenically related to t-PA (e.g., see the Western
analysis in Fig. 5B). (A) Analysis of t-PA from untreated cells. (B)
Analysis of t-PA from untreated cells (CONT; lanes 1 to 3 and 9 to
11) and of t-PA from cells treated for 8 h with 2 mM MDNM (lanes
5 to 7 and 13 to 15). Lane M contained molecular mass standards
(numbers at left in thousands).
results indicate that at least a subset of the N-linked oligo-
saccharides in Sf9 cell-derived t-PA is partially resistant to
endo-H; therefore, some processing of these oligosaccha-
rides has occurred in Sf9 cells. This observation was repro-
ducible; multiple experiments with different passages of
virus and cells, different lots and concentrations of both
enzymes, and numerous independent SDS-PAGE analyses
produced the same results.
A simple way to test the interpretation that Sf9 cells can
process some N-linked oligosaccharides arose from studies
designed to examine the influence of oligosaccharide proc-
essing on the secretion of t-PA from these cells (see below).
Both castanospermine and N-methyldeoxynojirimycin
(MDNM) are inhibitors of the cellular glucosidases that
mediate the initial steps in the processing of N-linked oligo-
saccharides (reviewed in reference 7). Neither of these
inhibitors prevented the secretion of t-PA from Sf9 cells (see
below). Thus, we were able to examine the endoglycosidase
sensitivity of a t-PA population for which oligosaccharide
processing had been artificially prevented. According to the
interpretation of the endoglycosidase results presented
above, t-PA from castanospermine- or MDNM-treated cells
should have been equally sensitive to both endo-H and
N-glycanase; this was indeed the case (Fig. 2B). Endo-H or
N-glycanase treatment of the extracellular t-PA from
MDNM-treated cells produced the same 58 kDa end product
(lanes 5 and 6), while the extracellular t-PA from control
cells was, again, partially resistant to endo-H (lanes 1, 2, and
3). Identical results were obtained in endoglycosidase anal-
yses of t-PA isolated from castanospermine-treated cells
(data not shown). These results strongly support the inter-
pretation that at least a subset of the N-linked oligosaccha-
rides of human t-PA expressed in Sf9 cells has been proc-
essed to an endo-H-resistant form.
Another conclusion to be drawn from the endoglycosidase
experiments is that the difference in the sizes of the intra-
cellular and extracellular forms of t-PA is not related to N
glycosylation, because the completely deglycosylated forms
(N-glycanase reaction products) are still different in size.
Therefore, these two forms of t-PA probably differ in their
primary structures. One speculation is that the intracellular
form still contains the prosequence of about 15 amino acids,
while the secreted form does not. This model requires that
the product synthesized in the presence of TM also lacks the
prosequence to explain its comigration with the deglycosy-
lated extracellular product and the fact that it is smaller than
the deglycosylated intracellular product. Proteolytic re-
moval of the prosequence of intracellular nonglycosylated
t-PA might be anticipated on the basis of increased sensitiv-
ity of the polypeptide to proteolysis in the absence of N
glycosylation (22, 23).
Kinetics of t-PA glycosylation and secretion in Sf9 cells.
Pulse-chase analyses were used to evaluate the kinetics with
which human t-PA entered and exited the secretory pathway
in baculovirus-infected Sf9 cells. Infected cell cultures were
pulse-labeled for 5 or 15 min at 24 hpi and chased in the
presence of excess amino acids and 10 jig of cycloheximide
per ml as described in Materials and Methods. Samples were
removed from the cultures at various intervals and clarified,
and t-PA was isolated from the extracellular and intracellular
fractions by immunoprecipitation and analyzed by SDS-
PAGE. In the absence of an inhibitor (e.g., TM), a nongly-
cosylated form of t-PA was never detected, even when the
cells were labeled for only 5 min (Fig. 3). In control
experiments, we found that the mass of t-PA synthesized in
vitro was clearly different from that of t-PA isolated from the
intracellular fraction of 373-t-PA-infected Sf9 cells, proving
that a nonglycosylated form of t-PA could have been de-
tected (data not shown). Thus, recognition of the mammalian
t-PA signal sequence occurs with high efficiency in Sf9 cells,
followed by rapid translocation across the membrane of the
rough endoplasmic reticulum and N glycosylation, probably
in a cotranslational fashion. The data do not eliminate the
theoretical possibility, however, that signal sequence recog-
nition is followed by translational arrest without reinitiation.
Therefore, although the pulse-chase experiments indicate
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FIG. 3. Pulse-chase analysis of t-PA biosynthesis and secretion.
373-t-PA-infected Sf9 cells cultured in suspension were pulse-
labeled for 5 min at 24 hpi with 500 ,uCi of [35S]Translabel per ml and
chased as described in Materials and Methods. Samples were taken
immediately after the labeling period (O min) or at various times
afterwards (numbers at the top indicate time in minutes), and t-PA
was immunoprecipitated from the extracellular (X) or intracellular
fractions (I) and analyzed by SDS-PAGE. t-PA immunoprecipitated
from TM-treated cells served as a marker for nonglycosylated t-PA,
as indicated in the legend to Fig. 2. Lane M is as in Fig. 2.
that recognition of the t-PA signal sequence is an efficient
process, they cannot provide a true measure of the efficiency
with which newly synthesized t-PA molecules enter the
secretory pathway.
With chase times of up to 2 (Fig. 3) or even 16 (data not
shown) h, there was no apparent change in the mass of t-PA
4
3
XC TPA cpm
(103)
2
0
in the intracellular fraction; the smaller form of t-PA was
detected only in the extracellular fraction. This result sug-
gests that conversion of the larger form of t-PA to the smaller
form, which is probably not related to N glycosylation,
occurs simultaneously with or shortly after its exit from the
cell.
The rate of secretion of human t-PA from 373-t-PA-
infected Sf9 cells was determined from pulse-chase experi-
ments by quantitation of the 62 kDa extracellular t-PA bands
as a function of chase time (Fig. 4). The results indicate that
the secretion of t-PA occurs rather slowly, with a half-time
of about 1.6 h. In light of the apparent rapidity of transloca-
tion and N glycosylation, this result suggests that a rate-
limiting step(s) in the secretion of t-PA occurs later, during
the subsequent processing of the polypeptide and its move-
ment out of the Sf9 cell.
Role of glycosylation in the secretion of t-PA from insect
cells. TM was used to evaluate the role ofN glycosylation in
the secretion of t-PA from Sf9 cells. The conditions of TM
treatment required for the inhibition ofN glycosylation were
established by measuring the incorporation of either [35"]
methionine or [3H]mannose into total acid-precipitable pro-
tein from 373-t-PA-infected Sf9 cells. The results showed
that an 8-h treatment with 1.0 ,ug ofTM per ml provided 79%
inhibition of control mannose incorporation, with no inhibi-
tion of overall protein synthesis; in fact, a minor stimulation
(114% of the control) was observed (data not shown). Under
these conditions, virtually no extracellular t-PA was detect-
able by either immunoprecipitation (Fig. 5A) or Western
analysis (Fig. 5B). In addition, t-PA accumulated with an
altered intracellular distribution within the TM-treated Sf9
cells; significant amounts were extractable from the NP-40-
insoluble fraction of TM-treated cells, while very little was
extractable from the NP-40-insoluble fraction of untreated
cells (Fig. SB). These results indicate that the nonglycosy-
lated t-PA product is not secreted from TM-treated Sf9 cells;
instead, it appears to associate with an insoluble subcellular
compartment. This model is consistent with the observation
that several different polypeptides were strongly immuno-
precipitated from the intracellular fraction of TM-treated
0 4 8 12
CHASE TIME (HRS)
1 6
FIG. 4. Kinetics of t-PA secretion from Sf9 cells. Duplicate cultures of 373-t-PA-infected Sf9 cells cultured in suspension were
pulse-labeled for 15 min at 24 hpi with 200 ,uCi of [35S]Translabel per ml and chased as described in Materials and Methods. Samples were
taken immediately after the labeling period or after various times of chase, and t-PA was immunoprecipitated from the extracellular fraction.
The immunoprecipitates were resolved by SDS-PAGE, and t-PA bands were excised, solubilized, and quantitated by liquid scintillation
spectroscopy. Results were plotted as total extracellular t-PA (XC TPA) versus chase time, with the values obtained for the zero-time samples
subtracted as background. The two separate plots represent independent results obtained with the duplicate cultures. The half-time for
secretion was determined separately from each curve and was found in both cases to be 1.6 h.
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FIG. 5. Effect ofTM treatment on t-PA secretion from Sf9 cells.
(A) 373-t-PA-infected Sf9 cells were untreated (0) or treated for 8 h
with 0.5, 1.0, or 2.0 jg ofTM per ml, as indicated above the lanes.
The cells were labeled with 100 jCi of [35S]Translabel per ml from
20 to 24 hpi, corresponding to the last half of the TM treatment
period. Extracellular (X), intracellular (I), and insoluble (IN) frac-
tions were prepared, and t-PA was immunoprecipitated and ana-
lyzed by SDS-PAGE. (B) Cells were mock infected or infected with
wild-type baculovirus (AcMNPV) or 373-t-PA and were untreated or
treated with 1.0 ,ug of TM per ml, as indicated above the lanes.
Extracellular (X), intracellular (I), and insoluble (IN) fractions were
prepared, and proteins were resolved directly by SDS-PAGE and
analyzed by Western transfer with goat anti-t-PA as the probe as
described in Materials and Methods. Numbers at right are as in Fig.
1.
cells (Fig. SA), while only one polypeptide (58 kDa) proved
to be specifically immunoreactive (Fig. 5B). The other
proteins might have been coimmunoprecipitated by virtue of
a physical association with the 58-kDa nonglycosylated t-PA
product, as noted above.
The biosynthesis and secretion of t-PA also were exam-
ined in Sf9 cells treated with inhibitors which interfere with
the processing of N-linked oligosaccharide side chains. The
glucosidase inhibitors MDNM and castanospermine were
clearly effective in Sf9 cells, as evidenced by changes in the
mass of t-PA relative to the control (Fig. 6A). The specifi-
cally immunoreactive t-PA polypeptides were detected by
Western analysis (Fig. 6B). A comparison of Fig. 6A and B
reveals that several polypeptides were immunoprecipitated
FIG. 6. Effects of oligosaccharide processing inhibitors on t-PA
secretion from Sf9 cells. 373-t-PA-infected Sf9 cells were treated
beginning at 16 hpi with Grace medium alone (C) or with medium
containing 2.0 mM MDNM, 0.2 mM castanospermine (CS), 1.0 mM
deoxymannojirimycin (DMN), 0.015 mM swainsonine (SW), or 1 jLg
ofTM per ml. Each inhibitor was prepared as a lOx stock in Grace
medium, except for TM, which was prepared as a 1,000x stock in
ethanol, and inhibitors were stored at -70°C prior to use. All
inhibitors were purchased from Genzyme, except for castanosper-
mine and TM, which were purchased from Behring Diagnostics (San
Diego), Calif.). The cells were labeled with 100 ,iCi of [35S]Translabel
per ml from 20 to 24 hpi, and extracellular (XC) and intracellular (IC)
fractions were prepared. (A) t-PA was immunoprecipitated from the
cell fractions and analyzed by SDS-PAGE. (B) Total proteins in
fractions were resolved by SDS-PAGE and subjected to Western
analysis with goat anti-t-PA as the probe as described in Materials
and Methods.
nonspecifically from inhibitor-treated cells, as was observed
for TM-treated cells. However, none of the inhibitors pre-
vented secretion of the incompletely processed glycopro-
tein. Furthermore, unlike TM, these inhibitors had no effect
on the solubility of intracellular t-PA (data not shown).
These findings suggest that, although N glycosylation in Sf9
cells is required directly or indirectly for the secretion of
t-PA, processing of the N-linked oligosaccharide side chains
is not.
Influence of virus infection on the secretion of t-PA from
insect cells. The influence of the ongoing baculovirus infec-
tion on the processing of t-PA in insect cells was evaluated
-97
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220 JARVIS AND SUMMERS
by measuring t-PA secretion at different times postinfection
and under different conditions of infection. Cells were in-
fected at different multiplicities (1, 10, or 20 PFU per cell)
and pulse-labeled for 4 h (about twice the half-time for
secretion) at various times postinfection. Extracellular, in-
tracellular, and insoluble fractions were prepared, and t-PA
was extracted and immunoprecipitated. The immunoprecip-
itates were resolved by SDS-PAGE, and t-PA bands were
quantitated. The peak time of expression and the absolute
amounts oft-PA synthesized were about the same at all three
multiplicities of infection, indicating that this variable has
little influence on the overall expression of t-PA (Fig. 7A).
The curve was slightly skewed at higher multiplicities, with
slightly higher amounts of synthesis occurring at earlier
times postinfection and slightly lower amounts occurring at
later times postinfection, but it is not known if these differ-
ences were significant. However, the time postinfection
during which the peak rate of expression occurred is firm, as
similar results have been observed for several different
recombinant proteins expressed in Sf9 cells (unpublished
data). When the amounts of secreted t-PA were related
directly to the amounts of intracellular t-PA at different times
postinfection, an astounding result was obtained (Fig. 7B).
Under all three conditions of infection, the secretion of t-PA
was clearly and dramatically inhibited at later times of
infection. This inhibition was not accompanied by an in-
crease in the relative amounts of t-PA in the insoluble
intracellular fraction (Fig. 7C). The exact reasons for this
effect are unknown at this time, nor is it known if this is a
general effect; i.e. if similar results would be observed for
other secretory proteins. However, the results suggest that
the Sf9 cell secretory pathway is compromised during the
later stages of baculovirus infection.
DISCUSSION
Human t-PA was expressed in Sf9 insect cells with a
recombinant baculovirus vector and was used as a model to
study the pathway of protein glycosylation and secretion in
these cells. Formally, the results of this study apply directly
only to human t-PA and Sf9 cells, the model glycoprotein
and cell line for which the data were derived. However, we
speculate that the results reflect the characteristics of the
lepidopteran insect cell pathway which accomplishes N
glycosylation and secretion of mammalian glycoproteins in
general and probably of naturally occurring insect glycopro-
teins as well.
The major intracellular form of human t-PA expressed in
baculovirus-infected Sf9 cells was a polypeptide of about 65
kDa, and it was secreted as a slightly smaller product of
about 62 kDa. A nonglycosylated t-PA precursor was not
detected intracellularly, even with short times of pulse-
labeling. This indicated that the signal sequence of human
t-PA was efficiently recognized in Sf9 cells and that one
result of this was the rapid translocation of the nascent
polypeptide across the rough endoplasmic reticulum mem-
brane, where it became immediately available for N glyco-
sylation. Many other mammalian glycoproteins have been
shown to undergo N glycosylation and secretion when
expressed in Sf9 cells by baculovirus vectors (reviewed in
reference 19), so this was not a surprising result. The
unexpected result was that the extracellular form of t-PA
was partially resistant to treatment with endo-H. In contrast
to the results of previous studies of mammalian glycopro-
teins expressed in Sf9 cells by baculovirus vectors (10, 17,
28, 44; reviewed in reference in 19), this finding suggested
1o0
IC TPA
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XC:Ic
12 20 28 36 44
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0.2
o0c
20 28 36 44
C
12 20 28 36 44
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FIG. 7. Influence of virus infection on t-PA secretion. Sf9 cells
were infected with 373-t-PA at multiplicities of infection of 1 (0), 10
(*), or 20 (U) PFU per cell and labeled for 4 h with 100 ,uCi of
[35S]Translabel per ml from 12 to 16, 20 to 24, 28 to 32, 36 to 40, or
44 to 48 hpi. After the labeling period, t-PA was immunoprecipitated
from extracellular (XC), intracellular (IC), and insoluble (IN) frac-
tions and was gel purified, and the t-PA bands were excised,
solubilized, and quantitated by liquid scintillation spectroscopy. (A)
Plot of total intracellular t-PA (IC TPA) as a function of time
postinfection. (B) Plot of the ratio of extracellular to intracellular
t-PA at various times postinfection. (C) Plot of the ratio of insoluble
to intracellular t-PA at various times postinfection.
that a high-mannose N-linked oligosaccharide may be proc-
essed to an endo-H-resistant form in these cells.
The precise structure of the endo-H-resistant oligosaccha-
ride(s) on the 62 kDa t-PA polypeptide secreted from Sf9
cells was not determined. In mammalian cells, resistance to
endo-H is acquired by the conversion of an oligosaccharide-
processing intermediate, [Asn]-GlcNAc2-Man5, to [Asn]-
GlcNAc2-Man3-GlcNAc by mannosidase II and N-acetylglu-
cosaminyltransferase I in the medial compartment of the
Golgi apparatus (reviewed in references 8 and 14). It is
m
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possible that a similar conversion takes place in Sf9 cells.
However, previous studies of mosquito and fruitfly cells
suggest that the processing of N-linked glycans is different in
insects; in these dipteran cells, the cotranslational addition
of a typical high-mannose oligosaccharide, GlcNAc2-Mang-
Glc3, is followed by the processing of about half of the total
N-linked glycans to a trimannosyl core, [Asn]-GlcNAc2-
Man3 (12). Further processing of the oligosaccharide does
not appear to take place, owing to the absence of the
requisite glycosyltransferase activities (5). If Sf9 cells also
lack these glycosyltransferase activities, then the triman-
nosyl core probably represents the fully processed oligosac-
charide(s) on the extracellular form of t-PA, because it is
endo-H resistant (39). Clearly, direct chemical analyses of
the processed oligosaccharides will be necessary to elucidate
their precise structures.
Although our endoglycosidase results show that a previ-
ously unrecognized degree of N-linked oligosaccharide proc-
essing may occur in baculovirus-infected Sf9 cells, it must be
emphasized that this probably does not occur for all N-
linked glycoproteins expressed in Sf9 cells or in other insect
cells. Only about half of the oligosaccharides in mosquito
cell glycoproteins contain a trimannosyl core structure; the
other half contain endo-H-sensitive structures with variable
numbers of mannose residues (12). The mature, secreted
form of arylphorin, the major hemolymph glycoprotein of
Manduca sexta (Lepidoptera), contains [Asn]-GlcNAc2-
Mang, an endo-H-sensitive structure (30). Similarly, the
mature forms of lipophorin, the major lipoprotein of the
locust, Locusta migratoria (Orthoptera), contain endo-H-
sensitive oligosaccharides with variable numbers of man-
nose residues from Mang to Man5 (21). Finally, it has been
shown that plasma membrane glycoproteins isolated from
mosquito cells contain three terminal glucose residues, in-
dicative of the transport of a completely nonprocessed
glycoprotein through the secretory pathway (4).
Additional information on the steps that constitute the N
glycosylation pathway in Sf9 cells was obtained by using
inhibitors of N-linked oligosaccharide processing. Both
castanospermine and MDNM caused an increase in the size
of intracellular t-PA, suggesting the presence of glucosidase
I and/or II activities in Sf9 cells. This result is consistent with
those of previous studies suggesting that terminal glucose
residues may be trimmed from N-linked oligosaccharides in
insect cells, as noted above. Deoxymannojirimycin had no
apparent affect on the size of t-PA, suggesting the absence of
mannosidase I. However, this result is probably an artifac-
tual one, as the removal of mannose residues has been
clearly documented in previous studies (12, 21), and this
must occur for an oligosaccharide to acquire endo-H resis-
tance. This conclusion is supported by the observation that
deoxymannojirimycin also fails to inhibit yeast mannosidase
I in vivo, even though it effectively inhibits the enzyme in
vitro (16). Swainsonine caused a slight retardation of t-PA,
suggesting the presence of mannosidase II activity in Sf9
cells, but not in a particularly convincing fashion. Direct
analysis of Sf9 cell extracts for the presence of each of these
putative enzymatic activities will be required to test these
tentative interpretations.
Studies on the rate of secretion of t-PA from Sf9 cells
indicated that this was a relatively slow process, with a
half-time of about 1.6 h. However, the absence of detectable
nonglycosylated t-PA in the cells suggested that entry into
the secretory pathway and N glycosylation occurred
quickly. Thus, a rate-limiting step(s) in the secretion of t-PA
from Sf9 cells probably occurs after translocation and N
glycosylation. It is possible that folding of the polypeptide
occurs slowly, as it contains 35 cysteine residues, some of
which are thought to participate in intramolecular disulfide
bonds to generate a complex folded structure (24). In previ-
ous studies, it has been shown that folding and/or supramo-
lecular assembly is a prerequisite for the movement of two
different viral glycoproteins through the secretory pathway
of mammalian cells (9, 15).
After enzymatic deglycosylation, the extracellular and
intracellular forms of t-PA still had different apparent mo-
lecular masses. This indicated that the difference in their
masses was not related to a difference in N glycosylation. On
the basis of comparisons to nonglycosylated t-PA produced
in the presence of TM, we speculated that the 65-kDa
intracellular form of t-PA retains, while the 62-kDa extracel-
lular form lacks, the amino-terminal prosequence of about 15
amino acids. A putative t-PA prosequence was first identi-
fied from the nucleotide sequence by Pennica and co-
workers (24), and its absence in the mature t-PA polypeptide
secreted from mammalian cells has been shown by direct
peptide sequencing (27). The fact that none of the 62-kDa
form was detected intracellularly suggests that the structural
modification accounting for its lower mass occurs simulta-
neously with or shortly after its exit from the cell.
Treatment of 373-t-PA infected Sf9 cells with TM pre-
vented the appearance of t-PA in the extracellular culture
medium. In contrast, inhibitors of N-linked oligosaccharide
processing had no detectable effect on the secretion of t-PA
from Sf9 cells. Together, these results suggest that N glyco-
sylation, but not processing of the N-linked oligosaccha-
rides, is directly or indirectly required in Sf9 cells for the
secretion of human t-PA. Previous studies have shown that
TM reduces the secretion of a naturally occurring insect cell
secretory glycoprotein, vitellogenin, in the cockroach, Blat-
tella germanica (Orthoptera), by about 60%)o (45). Similarly,
Charlton and Volkman (6) suggested that cell surface expres-
sion of the major AcMNPV glycoprotein, gP64, is dimin-
ished in IPLB-Sf21-AE cells treated with TM. From all of
these results, we tentatively speculate that N-linked carbo-
hydrate plays a functional role in the movement of some
glycoproteins through the secretory pathway of S. frugi-
perda cells and probably other insect cells as well. This
clearly is not a universal rule, however, as at least one
exception has already been described; a nonglycosylated
form of phaseolin, a plant storage glycoprotein, is secreted
from TM-treated Sf9 cells (3).
We do not know the mechanism by which N-linked
oligosaccharides function in the secretion of t-PA from Sf9
cells, but several possibilities may be addressed. One is that
the glycan provides a direct signal which targets t-PA for
secretion, possibly through recognition by a cellular recep-
tor. However, if this were true, inhibitors of oligosaccharide
processing would be expected to inhibit t-PA secretion,
because the structure of the unprocessed glycan would be
different from that of the processed glycan. A second possi-
bility is that the oligosaccharides protect the polypeptide
from proteolytic degradation, thereby influencing secretion
in an indirect way. Protease inhibitors can restore secretion
or cell surface expression of several mammalian glycopro-
teins in TM-blocked cells, supporting a protective role for
N-linked glycans (22, 23). However, we observed no differ-
ence when Sf9 cells were treated with eitherTM alone orTM
and protease inhibitors (500 Kallikrein inactivating units of
aprotinin per ml and 200 ,uM leupeptin); in either case, there
was no detectable extracellular t-PA (unpublished observa-
tions). A third possible mechanism is that a change in the
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222 JARVIS AND SUMMERS
physical properties of t-PA, such as its solubility in an
aqueous solvent, occurs in the absence of N glycosylation
and interferes with its progression through the Sf9 cell
secretory pathway. The finding that nonglycosylated t-PA
had an altered intracellular distribution, with unusually large
amounts in the NP-40-insoluble fraction of TM-treated cells,
is consistent with this possibility. Perhaps the nonglycosy-
lated form of t-PA associates tightly with relatively insoluble
cellular or viral polypeptides and this association inhibits the
transit of the nonglycosylated polypeptide through the secre-
tory pathway. This would explain why immunoprecipitation
of the nonglycosylated product resulted in the detection of
several other polypeptides which were antigenically unre-
lated to t-PA; as discussed above, these other proteins might
have been coimmunoprecipitated by virtue of a physical
association with nonglycosylated t-PA. A more speculative
notion is that this mechanism exists by design for the
removal of proteins recognized as aberrant by Sf9 cells. This
might represent an insect cell homolog of the mammalian cell
mechanism which is thought to prevent the premature export
of proteins prior to their acquisition of appropriate supramo-
lecular structure (2, 11, 20). If so, one or more of the proteins
coprecipitating with nonglycosylated t-PA could be an insect
cell version of the immunoglobulin-heavy-chain-binding pro-
tein, BiP (2, 11, 20). Arguing against this mechanism is the
observation that several proteins coprecipitated with t-PA
from Sf9 cells treated with inhibitors of N-linked oligosac-
charide processing, even though none of these agents com-
pletely prevented the secretion of t-PA. Finally, a possible
mechanism for the inhibition of t-PA secretion by TM
treatment is that inhibition of N glycosylation by TM elimi-
nates the function of a cellular protein(s) required for the
process of protein secretion from Sf9 cells. On the basis of
our current observations, we are unable to either support or
refute this possibility.
Diflerences in the multiplicity of baculovirus infection did
not appear to influence either the level of absolute expres-
sion or the relative amounts of secretion of human t-PA
expressed in Sf9 cells. However, the relative amounts of
secreted t-PA decreased dramatically with increasing time of
infection. We speculate that this reflects a direct or indirect
effect of baculovirus infection on the host cell secretory
pathway. It is unlikely that the accumulation of t-PA simply
overwhelms the Sf9 secretory apparatus, because t-PA was
expressed at relatively low levels (Luckow and Summers, in
press) and because the absolute, as well as the relative,
amounts of secreted t-PA were lower at later times of
infection. This suggests that one result of the Sf9-AcMNPV
interaction is an inhibitory effect on the secretory pathway
late in infection. With respect to the use of baculoviruses as
vectors for foreign gene expression, these findings indicate
that current vectors are suboptimal for the production of
secretory glycoproteins. In the future, we will investigate
ways to avoid late viral effects on host cells to optimize the
baculovirus vector approach for the expression of mamma-
lian secretory glycoproteins.
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ADDENDUM IN PROOF
While this manuscript was under review, we became
aware that other investigators using the baculovirus expres-
sion system have recently found that Sf9 cells are capable of
processing some N-linked oligosaccharide side chains to a
state of endo-H resistance. The specific glycoproteins for
which this was documented include the ligand-binding do-
main of the human insulin receptor (J. Sissom and L. Ellis,
submitted for publication), the extracellular domain of the
rat myelin-associated glycoprotein (P. W. Johnson, J. Attia,
C. D. Richardson, J. C. Roder, and R. J. Dunn, submitted
for publication), and human acid ,B-glucosidase (G. A. Gra-
bowski, W. R. White, and M. E. Grace, Enzyme, in press).
For the insulin receptor and myelin-associated glycoprotein,
the intracellular forms were completely endo-H sensitive,
while the extracellular forms displayed at least partial endo-
H resistance; secretion was accomplished in both cases by
deletion of the transmembrane anchor domains. For acid
3-glucosidase, the majority of the protein remained cell
associated but still exhibited partial resistance to endo-H.
Thus, it is apparent that processing of the N-linked oligosac-
charides of several different mammalian glycoproteins can
occur in Sf9 cells, strengthening the speculative conclusion
that Sf9 cells behave like other insect cells (see references 4,
5, 12, 21, and 30) in this respect.
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